End of life in haematology: quality of life predictors - retrospective cohort study.

Haematology patients are more likely to receive high intensity care near end of life (EOL) than patients with solid malignancy. Previous authors have suggested indicators of quality EOL for haematology patients, based on a solid oncology model. We conducted a retrospective chart review with the objectives of (1) determining our performance on these quality EOL indicators, (2) describing the timing of level of intervention (LOI) discussion and palliative care (PC) consultation prior to death and (3) evaluating whether goals of therapy (GOT), PC consultation and earlier LOI discussion are predictors of quality EOL. We identified patients who died from haematological malignancies between April 2014 and March 2016 (n=319) at four participating McGill University hospitals and performed retrospective chart reviews. We found that 17% of patients were administered chemotherapy less than 14 days prior to death, 20% of patients were admitted to intensive care, 14% were intubated and 5% were resuscitated less than 30 days prior to death, 18% of patients received blood transfusion less than 7 days prior to death and 67% of patients died in an acute care setting. LOI discussion and PC consultation occurred a median of 22 days (IQR 7-103) and 9 days (IQR 3-19) before death. Patients with non-curative GOT, PC consultation or discussed LOI were significantly less likely to have high intensity EOL outcomes. In this study, we demonstrate that LOI discussions, PC consults and physician established GOT are associated with quality EOL outcomes for patients with haematological malignancies.

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: TM is a board member of the International papilloma virus society. SS has received research support from Novartis, has sat on the scientific advisory board for Novartis and BMS-Celgene, and has acted as a consultant for Novartis, BMS-Celgene, Sierra Oncology, Constellation, Janssen, Astrazeneca, Abbvie and GSK. KD has acted as a consultant for Abbvie, Kite, Roche, Seagen, Novartis, BMS, Janssen and Beigene and has received honoraria from Incyte. SA has received research support from Novartis and has acted as a consultant and received honoraria from Palladin, Roche, Novartis, BMS, Janssen, Astra Zeneca and Pfizer.